Insurers must cover injectable HIV prevention drug — unless courts void mandate

The U.S. Preventive Services Task Force found that the HIV pre-exposure prophylaxis drugs provide a “substantial net benefit” for those who are at higher risk of HIV.

Related Keywords

Texas ,United States ,San Francisco ,California ,Australia ,Boston ,Massachusetts ,Netherlands ,Jonathan Mermin ,Hyman Scott ,Kenneth Mayer ,Jeremiah Johnson ,Elizabeth Kaplan ,Prevention National Center ,San Francisco Department Of Public Health ,Harvard Law School ,Centers For Disease ,Fenway Institute ,Drug Administration ,Us Circuit Court ,Supreme Court ,Gilead Science Truvada ,Viiv Healthcare ,Affordable Care Act ,Disease Control ,National Center ,Viral Hepatitis ,San Francisco Department ,Public Health ,Hiv Prevention ,Hiv Epidemic ,Health Insurers ,Truvada ,Ruvada And Descovy ,